TY - BOOK PY - 2019 DA - 2019// TI - Asthma Management and Prevention for Adults and children older than 5 years ID - ref1 ER - TY - JOUR AU - Wenzel, S. E. PY - 2012 DA - 2012// TI - Asthma phenotypes: the evolution from clinical to molecular approaches JO - Nat Med VL - 18 UR - https://doi.org/10.1038/nm.2678 DO - 10.1038/nm.2678 ID - Wenzel2012 ER - TY - JOUR AU - Stanojevic, S. AU - Moores, G. AU - Gershon, A. S. AU - Bateman, E. D. AU - Cruz, A. A. PY - 2012 DA - 2012// TI - Global asthma prevalence in adults: findings from the cross-sectional world health survey JO - BMC Public Health VL - 12 UR - https://doi.org/10.1186/1471-2458-12-204 DO - 10.1186/1471-2458-12-204 ID - Stanojevic2012 ER - TY - JOUR AU - Wenzel, S. E. PY - 2006 DA - 2006// TI - Asthma: defining of the persistent adult phenotypes JO - Lancet. VL - 368 UR - https://doi.org/10.1016/S0140-6736(06)69290-8 DO - 10.1016/S0140-6736(06)69290-8 ID - Wenzel2006 ER - TY - JOUR AU - Woodruff, P. G. AU - Modrek, B. AU - Choy, D. F. AU - Jia, G. AU - Abbas, A. R. AU - Ellwanger, A. PY - 2009 DA - 2009// TI - T-helper type 2–driven inflammation defines major subphenotypes of asthma JO - Am J Respir Crit Care Med VL - 180 UR - https://doi.org/10.1164/rccm.200903-0392OC DO - 10.1164/rccm.200903-0392OC ID - Woodruff2009 ER - TY - JOUR AU - Zeiger, R. S. AU - Schatz, M. AU - Li, Q. AU - Chen, W. AU - Khatry, D. B. AU - Gossage, D. PY - 2014 DA - 2014// TI - High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma JO - J Allergy Clin Immunol Pract VL - 2 UR - https://doi.org/10.1016/j.jaip.2014.06.005 DO - 10.1016/j.jaip.2014.06.005 ID - Zeiger2014 ER - TY - JOUR AU - Moore, W. C. AU - Meyers, D. A. AU - Wenzel, S. E. AU - Teague, W. G. AU - Li, H. AU - Li, X. PY - 2010 DA - 2010// TI - Identification of asthma phenotypes using cluster analysis in the severe asthma research program JO - Am J Respir Crit Care Med VL - 181 UR - https://doi.org/10.1164/rccm.200906-0896OC DO - 10.1164/rccm.200906-0896OC ID - Moore2010 ER - TY - JOUR AU - Hekking, P. W. AU - Wener, R. R. AU - Amelink, M. AU - Zwinderman, A. H. AU - Bouvy, M. L. AU - Bel, E. H. PY - 2015 DA - 2015// TI - The prevalence of severe refractory asthma JO - J Allergy Clin Immunol VL - 135 UR - https://doi.org/10.1016/j.jaci.2014.08.042 DO - 10.1016/j.jaci.2014.08.042 ID - Hekking2015 ER - TY - JOUR AU - Lai, C. K. AU - Beasley, R. AU - Crane, J. AU - Foliaki, S. AU - Shah, J. AU - Weiland, S. PY - 2009 DA - 2009// TI - Global variation in the prevalence and severity of asthma symptoms: phase three of the international study of asthma and allergies in childhood (ISAAC) JO - Thorax. VL - 64 UR - https://doi.org/10.1136/thx.2008.106609 DO - 10.1136/thx.2008.106609 ID - Lai2009 ER - TY - STD TI - Global-Initiative-for-Asthma. Difficult-to-treat & severe asthma in adolescent and adult patients diagnosis and management 2019 [Available from: https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf. Accessed May 2019. UR - https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf ID - ref10 ER - TY - JOUR AU - Cowan, D. C. AU - Cowan, J. O. AU - Palmay, R. AU - Williamson, A. AU - Taylor, D. R. PY - 2010 DA - 2010// TI - The effects of steroid therapy on inflammatory cell subtypes in asthma JO - Thorax. VL - 65 UR - https://doi.org/10.1136/thx.2009.126722 DO - 10.1136/thx.2009.126722 ID - Cowan2010 ER - TY - JOUR AU - Fahy, J. V. PY - 2015 DA - 2015// TI - Type 2 inflammation in asthma--present in most, absent in many JO - Nat Rev Immunol. VL - 15 UR - https://doi.org/10.1038/nri3786 DO - 10.1038/nri3786 ID - Fahy2015 ER - TY - JOUR AU - Corren, J. AU - Parnes, J. R. AU - Wang, L. AU - Mo, M. AU - Roseti, S. L. AU - Griffiths, J. M. PY - 2017 DA - 2017// TI - Tezepelumab in adults with uncontrolled asthma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1704064 DO - 10.1056/NEJMoa1704064 ID - Corren2017 ER - TY - JOUR AU - Neighbour, H. AU - Boulet, L. P. AU - Lemiere, C. AU - Sehmi, R. AU - Leigh, R. AU - Sousa, A. PY - 2014 DA - 2014// TI - Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial JO - Clin Exp Allergy VL - 44 UR - https://doi.org/10.1111/cea.12244 DO - 10.1111/cea.12244 ID - Neighbour2014 ER - TY - JOUR AU - Pavord, I. D. AU - Korn, S. AU - Howarth, P. AU - Bleecker, E. R. AU - Buhl, R. AU - Keene, O. N. PY - 2012 DA - 2012// TI - Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial JO - Lancet VL - 380 UR - https://doi.org/10.1016/S0140-6736(12)60988-X DO - 10.1016/S0140-6736(12)60988-X ID - Pavord2012 ER - TY - JOUR AU - Bain, G. AU - King, C. AU - Brittain, J. AU - Hartung, J. AU - Dearmond, I. AU - Stearns, B. PY - 2012 DA - 2012// TI - Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2 JO - J Clin Pharmacol VL - 52 UR - https://doi.org/10.1177/0091270011421912 DO - 10.1177/0091270011421912 ID - Bain2012 ER - TY - JOUR AU - X-w, C. AU - Zhang, Y. AU - Wang, H. AU - Wang, W. PY - 2008 DA - 2008// TI - Effect of ligustrazine injection on levels of interleukin-4 and interferon-γ in patients with bronchial asthma JO - Chin J Integr Med VL - 14 UR - https://doi.org/10.1007/s11655-008-0217-y DO - 10.1007/s11655-008-0217-y ID - X-w2008 ER - TY - JOUR AU - Corren, J. AU - Lemanske, R. F. AU - Hanania, N. A. AU - Korenblat, P. E. AU - Parsey, M. V. AU - Arron, J. R. PY - 2011 DA - 2011// TI - Lebrikizumab treatment in adults with asthma JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1106469 DO - 10.1056/NEJMoa1106469 ID - Corren2011 ER - TY - JOUR AU - Castro, M. AU - Corren, J. AU - Pavord, I. D. AU - Maspero, J. AU - Wenzel, S. AU - Rabe, K. F. PY - 2018 DA - 2018// TI - Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1804092 DO - 10.1056/NEJMoa1804092 ID - Castro2018 ER - TY - JOUR AU - Oh, C. h. a. d. K. AU - Leigh, R. i. c. h. a. r. d. AU - McLaurin, K. i. m. m. i. e. K. AU - Kim, K. e. u. n. p. y. o. AU - Hultquist, M. i. c. k. i. AU - Molfino, N. e. s. t. o. r. A. PY - 2013 DA - 2013// TI - A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma JO - Respiratory Research VL - 14 UR - https://doi.org/10.1186/1465-9921-14-93 DO - 10.1186/1465-9921-14-93 ID - Oh2013 ER - TY - STD TI - Omalizumab for asthma in adults and children [Internet]. The Cochrane Library. 2014 [cited 23 November 2017]. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003559.pub4/epdf. UR - http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003559.pub4/epdf ID - ref21 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altman, D. G. PY - 2009 DA - 2009// TI - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement JO - J Clin Epidemiol VL - 62 UR - https://doi.org/10.1016/j.jclinepi.2009.06.005 DO - 10.1016/j.jclinepi.2009.06.005 ID - Moher2009 ER - TY - JOUR AU - Lugogo, N. AU - Domingo, C. AU - Chanez, P. AU - Leigh, R. AU - Gilson, M. J. AU - Price, R. G. PY - 2016 DA - 2016// TI - Long-term efficacy and safety of Mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label JO - Phase IIIb Study Clinical therapeutics VL - 38 ID - Lugogo2016 ER - TY - JOUR AU - Murphy, K. AU - Jacobs, J. AU - Bjermer, L. AU - Fahrenholz, J. M. AU - Shalit, Y. AU - Garin, M. PY - 2017 DA - 2017// TI - Long-term safety and efficacy of Reslizumab in patients with eosinophilic asthma JO - J Aller Cl Imm-Pract VL - 5 UR - https://doi.org/10.1016/j.jaip.2017.08.024 DO - 10.1016/j.jaip.2017.08.024 ID - Murphy2017 ER - TY - JOUR AU - Bel, E. H. AU - Wenzel, S. E. AU - Thompson, P. J. AU - Prazma, C. M. AU - Keene, O. N. AU - Yancey, S. W. PY - 2014 DA - 2014// TI - Oral glucocorticoid-sparing effect of Mepolizumab in eosinophilic asthma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1403291 DO - 10.1056/NEJMoa1403291 ID - Bel2014 ER - TY - JOUR AU - Nair, P. AU - Pizzichini, M. M. M. AU - Kjarsgaard, M. AU - Inman, M. D. AU - Efthimiadis, A. AU - Pizzichini, E. PY - 2009 DA - 2009// TI - Mepolizumab for prednisone-dependent asthma with sputum eosinophilia JO - N Engl J Med VL - 360 UR - https://doi.org/10.1056/NEJMoa0805435 DO - 10.1056/NEJMoa0805435 ID - Nair2009 ER - TY - JOUR AU - Normansell, R. AU - Walker, S. AU - Milan, S. J. AU - Walters, E. H. AU - Nair, P. PY - 2014 DA - 2014// TI - Omalizumab for asthma in adults and children JO - Cochrane Database Syst Rev VL - 1 ID - Normansell2014 ER - TY - STD TI - Higgins JG, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0: The Cochrane Collaboration; 2011 [Available from: www.handbook.cochrane.org. Accessed May 2019. UR - http://www.handbook.cochrane.org ID - ref28 ER - TY - JOUR AU - Dobler, C. l. a. u. d. i. a. C. AU - Wilson, M. i. c. h. a. e. l. E. AU - Murad, M. H. a. s. s. a. n. PY - 2018 DA - 2018// TI - A pulmonologist's guide to understanding network meta-analysis JO - European Respiratory Journal VL - 52 UR - https://doi.org/10.1183/13993003.00525-2018 DO - 10.1183/13993003.00525-2018 ID - Dobler2018 ER - TY - STD TI - Lin L, Zhang J, Hodges JS, Chu H. Performing arm-based network meta-analysis in R with the pcnetmeta package. J Stat Softw. 2017;80. ID - ref30 ER - TY - BOOK AU - Team, R. C. PY - 2018 DA - 2018// TI - R: A language and environment for statistical computing PB - R Foundation for Statistical Computing CY - Vienna ID - Team2018 ER - TY - JOUR AU - Lajeunesse, M. J. PY - 2016 DA - 2016// TI - Facilitating systematic reviews, data extraction and meta-analysis with the metagear package for r JO - Methods Ecol Evol VL - 7 UR - https://doi.org/10.1111/2041-210X.12472 DO - 10.1111/2041-210X.12472 ID - Lajeunesse2016 ER - TY - JOUR AU - Hanania, N. A. AU - Noonan, M. AU - Corren, J. AU - Korenblat, P. AU - Zheng, Y. AU - Fischer, S. K. PY - 2015 DA - 2015// TI - Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies JO - Thorax. VL - 70 UR - https://doi.org/10.1136/thoraxjnl-2014-206719 DO - 10.1136/thoraxjnl-2014-206719 ID - Hanania2015 ER - TY - JOUR AU - Hanania, N. A. AU - Korenblat, P. AU - Chapman, K. R. AU - Bateman, E. D. AU - Kopecky, P. AU - Paggiaro, P. PY - 2016 DA - 2016// TI - Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials JO - Lancet Respir Med VL - 4 UR - https://doi.org/10.1016/S2213-2600(16)30265-X DO - 10.1016/S2213-2600(16)30265-X ID - Hanania2016 ER - TY - JOUR AU - Panettieri, R. A. AU - Sjöbring, U. AU - Péterffy, A. AU - Wessman, P. AU - Bowen, K. AU - Piper, E. PY - 2018 DA - 2018// TI - Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials JO - Lancet Respir Med VL - 6 UR - https://doi.org/10.1016/S2213-2600(18)30184-X DO - 10.1016/S2213-2600(18)30184-X ID - Panettieri2018 ER - TY - JOUR AU - Ortega, H. G. AU - Liu, M. C. AU - Pavord, I. D. AU - Brusselle, G. G. AU - FitzGerald, J. M. AU - Chetta, A. PY - 2014 DA - 2014// TI - Mepolizumab treatment in patients with severe eosinophilic asthma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1403290 DO - 10.1056/NEJMoa1403290 ID - Ortega2014 ER - TY - JOUR AU - Castro, M. AU - Zangrilli, J. AU - Wechsler, M. E. AU - Bateman, E. D. AU - Brusselle, G. G. AU - Bardin, P. PY - 2015 DA - 2015// TI - Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials JO - Lancet Respir Med VL - 3 UR - https://doi.org/10.1016/S2213-2600(15)00042-9 DO - 10.1016/S2213-2600(15)00042-9 ID - Castro2015 ER - TY - JOUR AU - Bleecker, E. R. AU - FitzGerald, J. M. AU - Chanez, P. AU - Papi, A. AU - Weinstein, S. F. AU - Barker, P. PY - 2016 DA - 2016// TI - Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial JO - Lancet. VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)31324-1 DO - 10.1016/S0140-6736(16)31324-1 ID - Bleecker2016 ER - TY - JOUR AU - FitzGerald, J. M. AU - Bleecker, E. R. AU - Nair, P. AU - Korn, S. AU - Ohta, K. AU - Lommatzsch, M. PY - 2016 DA - 2016// TI - Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial JO - Lancet. VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)31322-8 DO - 10.1016/S0140-6736(16)31322-8 ID - FitzGerald2016 ER - TY - JOUR AU - Park, H. S. AU - Kim, M. K. AU - Imai, N. AU - Nakanishi, T. AU - Adachi, M. AU - Ohta, K. PY - 2016 DA - 2016// TI - A phase 2a study of Benralizumab for patients with eosinophilic asthma in South Korea and Japan JO - Int Arch Allergy Immunol VL - 169 UR - https://doi.org/10.1159/000444799 DO - 10.1159/000444799 ID - Park2016 ER - TY - JOUR AU - Nowak, R. M. AU - Parker, J. M. AU - Silverman, R. A. AU - Rowe, B. H. AU - Smithline, H. AU - Khan, F. PY - 2015 DA - 2015// TI - A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma JO - Am J Emerg Med VL - 33 UR - https://doi.org/10.1016/j.ajem.2014.09.036 DO - 10.1016/j.ajem.2014.09.036 ID - Nowak2015 ER - TY - JOUR AU - Castro, M. AU - Wenzel, S. E. AU - Bleecker, E. R. AU - Pizzichini, E. AU - Kuna, P. AU - Busse, W. W. PY - 2014 DA - 2014// TI - Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study JO - Lancet Respir Med VL - 2 UR - https://doi.org/10.1016/S2213-2600(14)70201-2 DO - 10.1016/S2213-2600(14)70201-2 ID - Castro2014 ER - TY - JOUR AU - Lundh, A. AU - Lexchin, J. AU - Mintzes, B. AU - Schroll, J. B. AU - Bero, L. PY - 2018 DA - 2018// TI - Industry sponsorship and research outcome: systematic review with meta-analysis JO - Intensive Care Med VL - 44 UR - https://doi.org/10.1007/s00134-018-5293-7 DO - 10.1007/s00134-018-5293-7 ID - Lundh2018 ER - TY - JOUR AU - Lundh, A. AU - Lexchin, J. AU - Mintzes, B. AU - Schroll, J. B. AU - Bero, L. PY - 2017 DA - 2017// TI - Industry sponsorship and research outcome JO - Cochrane Database Syst Rev VL - 2 ID - Lundh2017 ER - TY - JOUR AU - Lexchin, J. AU - Bero, L. A. AU - Djulbegovic, B. AU - Clark, O. PY - 2003 DA - 2003// TI - Pharmaceutical industry sponsorship and research outcome and quality: systematic review JO - BMJ. VL - 326 UR - https://doi.org/10.1136/bmj.326.7400.1167 DO - 10.1136/bmj.326.7400.1167 ID - Lexchin2003 ER - TY - JOUR AU - Ferguson, G. T. AU - FitzGerald, J. M. AU - Bleecker, E. R. AU - Laviolette, M. AU - Bernstein, D. AU - LaForce, C. PY - 2017 DA - 2017// TI - Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet Respir Med VL - 5 UR - https://doi.org/10.1016/S2213-2600(17)30190-X DO - 10.1016/S2213-2600(17)30190-X ID - Ferguson2017 ER - TY - JOUR AU - Licona-Limón, P. AU - Kim, L. K. AU - Palm, N. W. AU - Flavell, R. A. PY - 2013 DA - 2013// TI - TH2, allergy and group 2 innate lymphoid cells JO - Nat Immunol VL - 14 UR - https://doi.org/10.1038/ni.2617 DO - 10.1038/ni.2617 ID - Licona-Limón2013 ER - TY - JOUR AU - Chupp, G. L. AU - Bradford, E. S. AU - Albers, F. C. AU - Bratton, D. J. AU - Wang-Jairaj, J. AU - Nelsen, L. M. PY - 2017 DA - 2017// TI - Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial JO - Lancet Respir Med VL - 5 UR - https://doi.org/10.1016/S2213-2600(17)30125-X DO - 10.1016/S2213-2600(17)30125-X ID - Chupp2017 ER - TY - JOUR AU - Haldar, P. AU - Brightling, C. E. AU - Hargadon, B. AU - Gupta, S. AU - Monteiro, W. AU - Sousa, A. PY - 2009 DA - 2009// TI - Mepolizumab and exacerbations of refractory eosinophilic asthma JO - N Engl J Med VL - 360 UR - https://doi.org/10.1056/NEJMoa0808991 DO - 10.1056/NEJMoa0808991 ID - Haldar2009 ER - TY - JOUR AU - Flood-Page, P. AU - Swenson, C. AU - Faiferman, I. AU - Matthews, J. AU - Williams, M. AU - Brannick, L. PY - 2007 DA - 2007// TI - A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma JO - Am J Respir Crit Care Med VL - 176 UR - https://doi.org/10.1164/rccm.200701-085OC DO - 10.1164/rccm.200701-085OC ID - Flood-Page2007 ER - TY - JOUR AU - Hom, S. AU - Pisano, M. PY - 2017 DA - 2017// TI - Reslizumab (Cinqair): an Interleukin-5 antagonist for severe asthma of the eosinophilic phenotype JO - P T VL - 42 ID - Hom2017 ER - TY - JOUR AU - Corren, J. AU - Weinstein, S. AU - Janka, L. AU - Zangrilli, J. AU - Garin, M. PY - 2016 DA - 2016// TI - Phase 3 study of Reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts JO - Chest. VL - 150 UR - https://doi.org/10.1016/j.chest.2016.03.018 DO - 10.1016/j.chest.2016.03.018 ID - Corren2016 ER - TY - JOUR AU - Bjermer, L. AU - Lemiere, C. AU - Maspero, J. AU - Weiss, S. AU - Zangrilli, J. AU - Germinaro, M. PY - 2016 DA - 2016// TI - Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study JO - Chest. VL - 150 UR - https://doi.org/10.1016/j.chest.2016.03.032 DO - 10.1016/j.chest.2016.03.032 ID - Bjermer2016 ER - TY - JOUR AU - Castro, M. AU - Mathur, S. AU - Hargreave, F. AU - Boulet, L. P. AU - Xie, F. AU - Young, J. PY - 2011 DA - 2011// TI - Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study JO - Am J Respir Crit Care Med VL - 184 UR - https://doi.org/10.1164/rccm.201103-0396OC DO - 10.1164/rccm.201103-0396OC ID - Castro2011 ER - TY - JOUR AU - Pelaia, C. AU - Calabrese, C. AU - Vatrella, A. AU - Busceti, M. T. AU - Garofalo, E. AU - Lombardo, N. PY - 2018 DA - 2018// TI - Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma JO - Biomed Res Int VL - 2018 UR - https://doi.org/10.1155/2018/4839230 DO - 10.1155/2018/4839230 ID - Pelaia2018 ER - TY - JOUR AU - Gandhi, N. A. AU - Bennett, B. L. AU - Graham, N. M. AU - Pirozzi, G. AU - Stahl, N. AU - Yancopoulos, G. D. PY - 2015 DA - 2015// TI - Targeting key proximal drivers of type 2 inflammation in disease JO - Nat Rev Drug Discov VL - 15 UR - https://doi.org/10.1038/nrd4624 DO - 10.1038/nrd4624 ID - Gandhi2015 ER - TY - JOUR AU - Noonan, M. AU - Korenblat, P. AU - Mosesova, S. AU - Scheerens, H. AU - Arron, J. R. AU - Zheng, Y. PY - 2013 DA - 2013// TI - Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids JO - J Allergy Clin Immunol VL - 132 UR - https://doi.org/10.1016/j.jaci.2013.03.051 DO - 10.1016/j.jaci.2013.03.051 ID - Noonan2013 ER - TY - JOUR AU - Popovic, B. AU - Breed, J. AU - Rees, D. G. AU - Gardener, M. J. AU - Vinall, L. M. AU - Kemp, B. PY - 2017 DA - 2017// TI - Structural characterisation reveals mechanism of IL-13-Neutralising monoclonal antibody Tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2 JO - J Mol Biol VL - 429 UR - https://doi.org/10.1016/j.jmb.2016.12.005 DO - 10.1016/j.jmb.2016.12.005 ID - Popovic2017 ER - TY - JOUR AU - Piper, E. AU - Brightling, C. AU - Niven, R. AU - Oh, C. AU - Faggioni, R. AU - Poon, K. PY - 2013 DA - 2013// TI - A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma JO - Eur Respir J VL - 41 UR - https://doi.org/10.1183/09031936.00223411 DO - 10.1183/09031936.00223411 ID - Piper2013 ER - TY - JOUR AU - Russell, R. J. AU - Chachi, L. AU - FitzGerald, J. M. AU - Backer, V. AU - Olivenstein, R. AU - Titlestad, I. L. PY - 2018 DA - 2018// TI - Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial JO - Lancet Respir Med VL - 6 UR - https://doi.org/10.1016/S2213-2600(18)30201-7 DO - 10.1016/S2213-2600(18)30201-7 ID - Russell2018 ER - TY - JOUR AU - Brightling, C. E. AU - Chanez, P. AU - Leigh, R. AU - O'Byrne, P. M. AU - Korn, S. AU - She, D. PY - 2015 DA - 2015// TI - Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial JO - Lancet Respir Med VL - 3 UR - https://doi.org/10.1016/S2213-2600(15)00197-6 DO - 10.1016/S2213-2600(15)00197-6 ID - Brightling2015 ER - TY - JOUR AU - Boever, E. H. AU - Ashman, C. AU - Cahn, A. P. AU - Locantore, N. W. AU - Overend, P. AU - Pouliquen, I. J. PY - 2014 DA - 2014// TI - Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial JO - J Allergy Clin Immunol VL - 133 UR - https://doi.org/10.1016/j.jaci.2014.01.002 DO - 10.1016/j.jaci.2014.01.002 ID - Boever2014 ER - TY - JOUR AU - Maes, T. AU - Joos, G. F. AU - Brusselle, G. G. PY - 2012 DA - 2012// TI - Targeting interleukin-4 in asthma: lost in translation? JO - Am J Respir Cell Mol Biol VL - 47 UR - https://doi.org/10.1165/rcmb.2012-0080TR DO - 10.1165/rcmb.2012-0080TR ID - Maes2012 ER - TY - JOUR AU - Wenzel, S. AU - Castro, M. AU - Corren, J. AU - Maspero, J. AU - Wang, L. AU - Zhang, B. Z. PY - 2016 DA - 2016// TI - Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta(2) agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial JO - Lancet. VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)30307-5 DO - 10.1016/S0140-6736(16)30307-5 ID - Wenzel2016 ER - TY - JOUR AU - Wenzel, S. AU - Ford, L. AU - Pearlman, D. AU - Spector, S. AU - Sher, L. AU - Skobieranda, F. PY - 2013 DA - 2013// TI - Dupilumab in persistent asthma with elevated eosinophil levels JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1304048 DO - 10.1056/NEJMoa1304048 ID - Wenzel2013 ER - TY - STD TI - Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother. 2019:1–11. ID - ref66 ER - TY - JOUR AU - Lambrecht, B. N. AU - Hammad, H. PY - 2010 DA - 2010// TI - The role of dendritic and epithelial cells as master regulators of allergic airway inflammation JO - Lancet. VL - 376 UR - https://doi.org/10.1016/S0140-6736(10)61226-3 DO - 10.1016/S0140-6736(10)61226-3 ID - Lambrecht2010 ER - TY - JOUR AU - Busse, W. W. AU - Israel, E. AU - Nelson, H. S. AU - Baker, J. W. AU - Charous, B. L. AU - Young, D. Y. PY - 2008 DA - 2008// TI - Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial JO - Am J Respir Crit Care Med VL - 178 UR - https://doi.org/10.1164/rccm.200708-1200OC DO - 10.1164/rccm.200708-1200OC ID - Busse2008 ER - TY - JOUR AU - FitzGerald, J. M. AU - Bleecker, E. R. AU - Menzies-Gow, A. AU - Zangrilli, J. G. AU - Hirsch, I. AU - Metcalfe, P. PY - 2018 DA - 2018// TI - Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies JO - Lancet Respir Med VL - 6 UR - https://doi.org/10.1016/S2213-2600(17)30344-2 DO - 10.1016/S2213-2600(17)30344-2 ID - FitzGerald2018 ER - TY - JOUR AU - Parulekar, A. D. AU - Kao, C. C. AU - Diamant, Z. AU - Hanania, N. A. PY - 2018 DA - 2018// TI - Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs JO - Curr Opin Pulm Med VL - 24 UR - https://doi.org/10.1097/MCP.0000000000000436 DO - 10.1097/MCP.0000000000000436 ID - Parulekar2018 ER - TY - STD TI - Review (ICER) IfCaE. Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks 2018 [Available from: https://icer-review.org/wp-content/uploads/2018/04/ICER_Asthma_Draft_Report_092418v1.pdf. UR - https://icer-review.org/wp-content/uploads/2018/04/ICER_Asthma_Draft_Report_092418v1.pdf ID - ref71 ER - TY - JOUR AU - Kelly, E. A. AU - Esnault, S. AU - Liu, L. Y. AU - Evans, M. D. AU - Johansson, M. W. AU - Mathur, S. PY - 2017 DA - 2017// TI - Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma JO - Am J Respir Crit Care Med VL - 196 UR - https://doi.org/10.1164/rccm.201611-2234OC DO - 10.1164/rccm.201611-2234OC ID - Kelly2017 ER - TY - JOUR AU - Paul, W. E. AU - Zhu, J. PY - 2010 DA - 2010// TI - How are T(H)2-type immune responses initiated and amplified? JO - Nat Rev Immunol VL - 10 UR - https://doi.org/10.1038/nri2735 DO - 10.1038/nri2735 ID - Paul2010 ER - TY - JOUR AU - McKenzie, A. N. PY - 2014 DA - 2014// TI - Type-2 innate lymphoid cells in asthma and allergy JO - Ann Am Thorac Soc VL - 11 UR - https://doi.org/10.1513/AnnalsATS.201403-097AW DO - 10.1513/AnnalsATS.201403-097AW ID - McKenzie2014 ER - TY - JOUR AU - Brusselle, G. G. AU - Maes, T. AU - Bracke, K. R. PY - 2013 DA - 2013// TI - Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma JO - Nat Med VL - 19 UR - https://doi.org/10.1038/nm.3300 DO - 10.1038/nm.3300 ID - Brusselle2013 ER - TY - JOUR AU - Smith, S. G. AU - Chen, R. AU - Kjarsgaard, M. AU - Huang, C. AU - Oliveria, J. P. AU - O'Byrne, P. M. PY - 2016 DA - 2016// TI - Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia JO - J Allergy Clin Immunol VL - 137 UR - https://doi.org/10.1016/j.jaci.2015.05.037 DO - 10.1016/j.jaci.2015.05.037 ID - Smith2016 ER - TY - JOUR AU - Saglani, S. AU - Lui, S. AU - Ullmann, N. AU - Campbell, G. A. AU - Sherburn, R. T. AU - Mathie, S. A. PY - 2013 DA - 2013// TI - IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma JO - J Allergy Clin Immunol VL - 132 UR - https://doi.org/10.1016/j.jaci.2013.04.012 DO - 10.1016/j.jaci.2013.04.012 ID - Saglani2013 ER - TY - JOUR AU - George, L. AU - Brightling, C. E. PY - 2016 DA - 2016// TI - Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease JO - Ther Adv Chronic Dis VL - 7 UR - https://doi.org/10.1177/2040622315609251 DO - 10.1177/2040622315609251 ID - George2016 ER - TY - JOUR AU - Wagener, A. H. AU - Nijs, S. B. AU - Lutter, R. AU - Sousa, A. R. AU - Weersink, E. J. AU - Bel, E. H. PY - 2015 DA - 2015// TI - External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma JO - Thorax. VL - 70 UR - https://doi.org/10.1136/thoraxjnl-2014-205634 DO - 10.1136/thoraxjnl-2014-205634 ID - Wagener2015 ER - TY - STD TI - FDA. FDA working with manufacturers to withdraw Zinbryta from the market in the United States 2018 [Available from: FDA working with manufacturers to withdraw Zinbryta from the market in the United States. ID - ref80 ER - TY - JOUR AU - McQueen, R. B. AU - Sheehan, D. N. AU - Whittington, M. D. AU - Boven, J. F. M. AU - Campbell, J. D. PY - 2018 DA - 2018// TI - Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations JO - Pharmacoeconomics. VL - 36 UR - https://doi.org/10.1007/s40273-018-0658-x DO - 10.1007/s40273-018-0658-x ID - McQueen2018 ER - TY - JOUR AU - Molfino, N. A. AU - Kuna, P. AU - Leff, J. A. AU - Oh, C. K. AU - Singh, D. AU - Chernow, M. PY - 2016 DA - 2016// TI - Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma JO - BMJ Open VL - 6 UR - https://doi.org/10.1136/bmjopen-2015-007709 DO - 10.1136/bmjopen-2015-007709 ID - Molfino2016 ER -